Cargando…
Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression
Rectal use of a 1% tenofovir (TFV) gel is currently being evaluated for HIV prevention. While careful assessment of mucosal safety of candidate microbicides is a primary concern, tools to assess mucosal toxicity are limited. Mass spectrometry-based proteomics is a sensitive and high-throughput techn...
Autores principales: | Romas, Laura, Birse, Kenzie, Mayer, Kenneth H., Abou, Max, Westmacott, Garrett, Giguere, Rebecca, Febo, Irma, Cranston, Ross D., Carballo-Diéguez, Alex, McGowan, Ian, Burgener, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067863/ https://www.ncbi.nlm.nih.gov/pubmed/27316778 http://dx.doi.org/10.1089/aid.2015.0381 |
Ejemplares similares
-
Interactive Voice Response System: Data Considerations and Lessons Learned During a Rectal Microbicide Placebo Adherence Trial for Young Men Who Have Sex With Men
por: Bauermeister, Jose, et al.
Publicado: (2017) -
Mucosal effects of tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015) -
Correction: Mucosal effects for tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015) -
Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women
por: McGowan, Ian, et al.
Publicado: (2016) -
A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)
por: Mcgowan, Ian, et al.
Publicado: (2013)